Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
https://seekingalpha.com/article/4681344-nuvation-bio-strong-buy-off-acquisition-late-stage-lung-cancer-candidate?source=feed_tag_editors_picks
Mar 31, 2024 - Nuvation Bio's acquisition of taletrectinib, boosts market cap while ensuring years of independent funding with liquid assets. Read more on NUVB's prospects.
0
Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?source=feed_sector_healthcare
Apr 05, 2024 - The CAR T therapy Abecma has been approved for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. Read more here.
0
Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
https://seekingalpha.com/article/4683358-bruker-offers-upside-with-key-enabling-technologies-for-future-bio-pharma-research?source=feed_all_articles
Apr 11, 2024 - Bruker offers growth at reasonable price for investors and is well-positioned for healthy revenue growth in 2024. Find out why BRKR stock is a Buy.
0
Oppenheimer starts Q32 Bio at outperform, cites lead asset
https://seekingalpha.com/news/4088992-oppenheimer-starts-q32-bio-at-outperform-cites-lead-asset?source=feed_sector_healthcare
Apr 11, 2024 - Oppenheimer started coverage of Q32 Bio (QTTB) with an outperform rating, citing the market potential of the company’s lead drug asset, bempikibart. Read more here.
0
Better Buy: Bluebird Bio Vs. Novavax
https://www.fool.com/investing/2024/04/13/better-buy-bluebird-bio-vs-novavax/?source=iedfolrf0000001
Apr 13, 2024 - Who wins this face-to-face between two beaten-down biotechs?
0
Takeda said to have left industry trade group BIO
https://seekingalpha.com/news/4094442-takeda-leaves-industry-trade-group-bio?source=feed_sector_healthcare
Apr 25, 2024 - Takeda Pharmaceutical (TAK) joins Pfizer (PFE) in leaving the Biotechnology Innovation Organization, the top biotech lobbying group. Read more here.
0
INmune Bio provides update on Alzheimer's candidate XPro
https://seekingalpha.com/news/4096265-inmune-bio-provides-update-alzheimers-candidate-xpro?source=feed_sector_healthcare
Apr 30, 2024 - INmune Bio's experimental Alzheimer's treatment XPro shows promising results in stabilizing cognitive states of patients in compassionate use program. Read more here.
0
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
https://www.fool.com/investing/2023/12/15/down-30-in-a-week-what-in-the-world-is-going-on-wi/?source=iedfolrf0000001
Dec 15, 2023 - An expected big win is rapidly turning into a defeat.
0
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
https://www.fool.com/investing/2023/12/23/1-green-flag-and-1-red-flag-for-bluebird-bio-stock/?source=iedfolrf0000001
Dec 23, 2023 - The stock has been in the news lately.
0
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
https://www.fool.com/investing/2023/12/24/if-you-invested-10000-in-bluebird-bio-in-2018-this/?source=iedfolrf0000001
Dec 24, 2023 - Can things get better for this struggling stock?
0